Abstract
This chapter summarizes the application of electroretinogram, electrooculogram, and visual evoked potential in retinal toxicities caused by vigabatrin, hydroxychloroquine (Plaquenil), chloroquine, antipsychotics, cis-platinum, deferoxamine, digoxin, ethambutol, indomethacin, isotretinoin, ocular siderosis, phosphodiesterase type 5 Inhibitor, and quinine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hebert-Lalonde N, et al. Electrophysiological evidences of visual field alterations in children exposed to vigabatrin early in life. Pediatr Neurol. 2016;59:47–53.
Tao Y, et al. The vigabatrin induced retinal toxicity is associated with photopic exposure and taurine deficiency: an in vivo study. Cell Physiol Biochem. 2016;40(5):831–46.
Kjellstrom U, Andreasson S, Ponjavic V. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol. 2014;92(2):149–57.
Ruether K, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol. 1998;116(6):817–9.
Harding GF, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia. 2000;41(11):1420–31.
Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180–1.
Gross-Tsur V, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol. 2000;48(1):60–4.
Daneshvar H, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106(9):1792–8.
Schroeder CE, et al. Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs. Epilepsia. 1992;33 Suppl 5:S13–25.
Cosi V, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol. 1989;27(Suppl 1):61S–8S.
Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol. 2001;102(1):63–72.
Yang J, et al. Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors. PLoS One. 2012;7(8):e43889.
Vogel KR, et al. mTOR inhibition mitigates molecular and biochemical alterations of vigabatrin-induced visual field toxicity in mice. Pediatr Neurol. 2017;66:44–52 e1.
Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82–91.
Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2(7101):478–80.
Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol. 1967;64(2):245–52.
Ivanina TA, et al. A study of the mechanisms of chloroquine retinopathy. II. Chloroquine effect on protein synthesis of retina. Ophthalmic Res. 1989;21(3):272–7.
Gonasun LM, Potts AM. In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Investig Ophthalmol. 1974;13(2):107–15.
Ivanina TA, et al. A study of the mechanisms of chloroquine retinopathy. I. Chloroquine effect on lipid peroxidation of retina. Ophthalmic Res. 1989;21(3):216–20.
Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.
Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122(7):973–81.
Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond). 2010;24(2):340–6.
So SC, et al. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthalmic Surg Lasers Imaging. 2003;34(3):251–8.
Michaelides M, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30–9.
Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. Graefes Arch Clin Exp Ophthalmol. 2000;238(1):94–7.
Lai TY, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005;140(5):794–807.
Chang WH, et al. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine. Retina. 2008;28(10):1478–86.
Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity. Doc Ophthalmol. 2009;118(1):29–36.
Tsang AC, et al. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology. 2015;122(6):1239–1251 e4.
Moschos MN, et al. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol. 2004;108(1):47–53.
Tzekov RT, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc Ophthalmol. 2004;108(1):87–97.
Nair AA, Marmor MF. ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. Doc Ophthalmol. 2017;134(3):175–83.
Marmor MF, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.
Young B, Eggenberger E, Kaufman D. Current electrophysiology in ophthalmology: a review. Curr Opin Ophthalmol. 2012;23(6):497–505.
Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol. 2012;6:377–83.
Nebbioso M, et al. Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Clin Exp Optom. 2011;94(3):276–83.
Nebbioso M, Grenga R, Karavitis P. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. J Ocul Pharmacol Ther. 2009;25(3):249–58.
Bartel P, et al. Effects of chlorpromazine on pattern and flash ERGs and VEPs compared to oxazepam and to placebo in normal subjects. Electroencephalogr Clin Neurophysiol. 1990;77(5):330–9.
Neves MS, Jordon K, Dragt H. Extensive chorioretinopathy associated with very low dose thioridazine. Eye (Lond). 1990;4(Pt 5):767–70.
Hagopian V, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am J Psychiatry. 1966;123(1):97–100.
Kozy D, Doft BH, Lipkowitz J. Nummular thioridazine retinopathy. Retina. 1984;4(4):253–6.
Persad S, et al. Phototoxicity of chlorpromazine on retinal pigment epithelial cells. Curr Eye Res. 1988;7(1):1–9.
Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24(6):501–26.
Katz BJ, et al. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol. 2003;23(2):132–5.
Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol. 1993;84(3):237–46.
Wilding G, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3(12):1683–9.
Simon S, et al. Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012;60(4):315–7.
Kaplinsky C, et al. Deferoxamine (Desferal)-induced ocular toxicity. Pediatr Hematol Oncol. 1988;5(4):293–7.
Haimovici R, et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109(1):164–71.
Schmidt D, Finke J. Bull’s-eye maculopathy with deferoxamine treatment. Klin Monatsbl Augenheilkd. 2004;221(3):204–9.
Kertes PJ, Lee TK, Coupland SG. The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol. 2004;39(6):656–61.
Lely AH, van Enter CH. Large-scale digitoxin intoxication. Br Med J. 1970;3(5725):737–40.
Butler VP Jr, et al. Digitalis-induced visual disturbances with therapeutic serum digitalis concentrations. Ann Intern Med. 1995;123(9):676–80.
Robertson DM, Hollenhorst RW, Callahan JA. Ocular manifestations of digitalis toxicity. Discussion and report of three cases of central scotomas. Arch Ophthalmol. 1966;76(5):640–5.
Lawrenson JG, et al. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol. 2002;86(11):1259–61.
Renard D, et al. Spectrum of digoxin-induced ocular toxicity: a case report and literature review. BMC Res Notes. 2015;8:368.
Piltz JR, et al. Digoxin toxicity. Recognizing the varied visual presentations. J Clin Neuroophthalmol. 1993;13(4):275–80.
Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch Ophthalmol. 1981;99(9):1568–72.
Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol. 1994;112(6):807–12.
Landfried B, et al. Digoxin-induced retinal degeneration depends on rhodopsin. Cell Death Dis. 2017;8(3):e2670.
Kinoshita J, et al. Digoxin-induced reversible dysfunction of the cone photoreceptors in monkeys. Invest Ophthalmol Vis Sci. 2014;55(2):881–92.
Maehara S, et al. Detection of cone dysfunction induced by digoxin in dogs by multicolor electroretinography. Vet Ophthalmol. 2005;8(6):407–13.
Deeti S, O’Farrell S, Kennedy BN. Early safety assessment of human oculotoxic drugs using the zebrafish visualmotor response. J Pharmacol Toxicol Methods. 2014;69(1):1–8.
Kandel H, et al. Visual function in patients on ethambutol therapy for tuberculosis. J Ocul Pharmacol Ther. 2012;28(2):174–8.
Lai TY, et al. Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. Br J Ophthalmol. 2005;89(6):774–5.
Behbehani RS, et al. Multifocal ERG in ethambutol associated visual loss. Br J Ophthalmol. 2005;89(8):976–82.
Kardon RH, Morrisey MC, Lee AG. Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity. Semin Ophthalmol. 2006;21(4):215–22.
Lai TY, et al. Multifocal electroretinography changes in patients on ethambutol therapy. Eye (Lond). 2009;23(8):1707–13.
Liu Y, et al. Multifocal electroretinographic abnormalities in ethambutol-induced visual loss. J Neuroophthalmol. 2008;28(4):278–82.
Graham CM, Blach RK. Indomethacin retinopathy: case report and review. Br J Ophthalmol. 1988;72(6):434–8.
Madke B, Prasad K, Kar S. Isotretinoin-induced night blindness. Indian J Dermatol. 2015;60(4):424.
Weleber RG, et al. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol. 1986;104(6):831–7.
Mollan SP, et al. Does use of isotretinoin rule out a career in flying? Br J Ophthalmol. 2006;90(8):957–9.
Kannan NB, et al. Management of ocular siderosis: visual outcome and electroretinographic changes. J Ophthalmol. 2016;2016:7272465.
Mumcuoglu T, et al. An animal model (guinea pig) of ocular siderosis: histopathology, pharmacology, and electrophysiology. Curr Eye Res. 2015;40(3):314–20.
Faure C, et al. Functional and high resolution retinal imaging assessment in a case of ocular siderosis. Doc Ophthalmol. 2014;128(1):69–75.
Kuhn F, et al. Improvement of siderotic ERG. Eur J Ophthalmol. 1992;2(1):44–5.
Declercq SS. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation. Br J Ophthalmol. 1980;64(8):626–9.
Declercq SS, Meredith PC, Rosenthal AR. Experimental siderosis in the rabbit: correlation between electroretinography and histopathology. Arch Ophthalmol. 1977;95(6):1051–8.
Gupta S, et al. Sensitivity of multifocal electroretinography (mfERG) in detecting siderosis. Can J Ophthalmol. 2015;50(6):485–90.
Schechner R, et al. A long term follow up of ocular siderosis: quantitative assessment of the electroretinogram. Doc Ophthalmol. 1990;76(3):231–40.
Schocket SS, Lakhanpal V, Varma SD. Siderosis from a retained intraocular stone. Retina. 1981;1(3):201–7.
Eltony SA, Abdelhameed SY. Effect of chronic administration of sildenafil citrate (Viagra) on the histology of the retina and optic nerve of adult male rat. Tissue Cell. 2017;49(2. Pt B):323–35.
Coca MN, et al. Bilateral posterior ischemic optic neuropathy associated with the use of Sildenafil for pulmonary hypertension. Can J Ophthalmol. 2016;51(3):e96–9.
Moschos MM, Nitoda E. Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drug Des Devel Ther. 2016;8:3407–13.
Luu JK, et al. Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol. 2001;132(3):388–94.
Kinoshita J, et al. Sildenafil-induced reversible impairment of rod and cone phototransduction in monkeys. Invest Ophthalmol Vis Sci. 2015;56(1):664–73.
Nivison-Smith L, et al. Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. Exp Eye Res. 2014;128:43–56.
Jagle H, et al. Dose-dependency and time-course of electrophysiologic short-term effects of VIAGRA: a case study. Doc Ophthalmol. 2005;110(2–3):247–54.
Luke M, et al. Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. J Ocul Pharmacol Ther. 2005;21(4):305–14.
McKoy JM, et al. Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment. Commun Oncol. 2009;6(2):78–80.
Martins J, et al. Sildenafil acutely decreases visual responses in ON and OFF retinal ganglion cells. Invest Ophthalmol Vis Sci. 2015;56(4):2639–48.
Jung S, et al. Sildenafil improves functional and structural outcome of retinal injury following term neonatal hypoxia-ischemia. Invest Ophthalmol Vis Sci. 2016;57(10):4306–14.
Roy R, et al. Central serous chorioretinopathy following oral tadalafil intake. Clin Exp Optom. 2014;97(5):473–4.
Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008;28(4):606–9.
Coscas F, et al. Optical coherence tomography in tadalafil-associated retinal toxicity. Eur J Ophthalmol. 2012;22(5):853–6.
Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye (Lond). 2005;19(6):715–7.
Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol. 2000;118(2):291–2.
Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol. 2001;21(1):22–5.
Boshier A, Pambakian N, Shakir SA. A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil. Int J Clin Pharmacol Ther. 2002;40(9):422–3.
Dheer S, Rekhi GS, Merlyn S. Sildenafil associated anterior ischaemic optic neuropathy. J Assoc Physicians India. 2002;50:265.
Pomeranz HD, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(3):584–7.
Gruhn N, Fledelius HC. Unilateral optic neuropathy associated with sildenafil intake. Acta Ophthalmol Scand. 2005;83(1):131–2.
Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol. 2005;25(1):9–13.
Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol. 2005;123(3):399–400.
Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol. 2005;123(3):400–1.
Egan RA, Fraunfelder FW. Viagra and anterior ischemic optic neuropathy. Arch Ophthalmol. 2005;123(5):709–10.
Kim IG, Kim DY. Anterior ischemic optic neuropathy associated with udenafil. Korean J Ophthalmol. 2012;26(3):235–8.
Moloney JB, Hillery M, Fenton M. Two year electrophysiology follow-up in quinine amblyopia. A case report. Acta Ophthalmol. 1987;65(6):731–4.
Su D, et al. Quinine toxicity: multimodal retinal imaging and electroretinography findings. Retin Cases Brief Rep. 2017;11 Suppl 1:S102–6.
Gangitano JL, Keltner JL. Abnormalities of the pupil and visual-evoked potential in quinine amblyopia. Am J Ophthalmol. 1980;89(3):425–30.
Sato S. Toxic effects on the visual system of diaminodiphenoxybutane, quinine, and ethambutol in conscious dogs. Fundam Appl Toxicol. 1985;5(4):777–84.
Saeed MU, et al. Relatively spared central multifocal electroretinogram responses in acute quinine toxicity. BMJ Case Rep. 2011;2011.
Verdon W. Clinical electrophysiology in quinine induced retinal toxicity. Optom Vis Sci. 2008;85(1):17–26.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yu, M., Senatore, A., Iannaccone, A., Kheir, W.J., Creel, D. (2019). Characteristics of Visual Electrophysiology in Retinal Toxicities. In: Yu, M., Creel, D., Iannaccone, A. (eds) Handbook of Clinical Electrophysiology of Vision. Springer, Cham. https://doi.org/10.1007/978-3-030-30417-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-30417-1_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30416-4
Online ISBN: 978-3-030-30417-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)